Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
BIOLOGICAL

ABT-874

SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

BIOLOGICAL

etanercept

SQ injection 50 mg BIW

DRUG

placebo

SQ placebo injections for ABT-874 and etanercept

Trial Locations (42)

10016

Site Reference ID/Investigator# 10241, New York

14623

Site Reference ID/Investigator# 9787, Rochester

28401

Site Reference ID/Investigator# 10581, Wilmington

28601

Site Reference ID/Investigator# 9902, Hickory

30022

Site Reference ID/Investigator# 15201, Alpharetta

30078

Site Reference ID/Investigator# 9789, Snellville

30263

Site Reference ID/Investigator# 10262, Newnan

30327

Site Reference ID/Investigator# 10762, Atlanta

32204

Site Reference ID/Investigator# 10503, Jacksonville

33144

Site Reference ID/Investigator# 10266, Miami

33173

Site Reference ID/Investigator# 9901, Miami

33407

Site Reference ID/Investigator# 10501, West Palm Beach

35205

Site Reference ID/Investigator# 9984, Birmingham

35233

Site Reference ID/Investigator# 10605, Birmingham

37934

Site Reference ID/Investigator# 10643, Knoxville

40202

Site Reference ID/Investigator# 10265, Louisville

42303

Site Reference ID/Investigator# 15750, Owensboro

Site Reference ID/Investigator# 9790, Owensboro

45408

Site Reference ID/Investigator# 10504, Dayton

46168

Site Reference ID/Investigator# 15142, Plainfield

48059

Site Reference ID/Investigator# 9788, Fort Gratiot

48439

Site Reference ID/Investigator# 10604, Grand Blanc

53209

Site Reference ID/Investigator# 10321, Milwaukee

55432

Site Reference ID/Investigator# 10541, Fridley

60153

Site Reference ID/Investigator# 10666, Maywood

63110

Site Reference ID/Investigator# 10641, St Louis

68131

Site Reference ID/Investigator# 10606, Omaha

68144

Site Reference ID/Investigator# 10644, Omaha

72205

Site Reference ID/Investigator# 10502, Little Rock

75230

Site Reference ID/Investigator# 9981, Dallas

77598

Site Reference ID/Investigator# 9982, Webster

78229

Site Reference ID/Investigator# 10264, San Antonio

85251

Site Reference ID/Investigator# 10001, Scottsdale

90045

Site Reference ID/Investigator# 14701, Los Angeles

90404

Site Reference ID/Investigator# 10662, Santa Monica

92123

Site Reference ID/Investigator# 9785, San Diego

92697

Site Reference ID/Investigator# 10661, Irvine

93309

Site Reference ID/Investigator# 9985, Bakersfield

94589

Site Reference ID/Investigator# 10642, Vallejo

98101

Site Reference ID/Investigator# 10182, Seattle

06511

Site Reference ID/Investigator# 10263, New Haven

08009

Site Reference ID/Investigator# 9786, Berlin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Paragon Biomedical

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00710580 - Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter